Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases

 Arena Signs a Multi-Year Agreement with Beacon Discovery to Develop Therapies for Immune and Inflammatory Diseases

Arena Pharmaceutical Licenses Exclusive Worldwide Rights of Ralinepag (APD811) to United Therapeutics for $1.2B

Shots:

  • Beacon will take care of drug discovery activities while Arena will focus on development and commercialization of products for multiple immune and inflammatory diseases
  • The focus of the agreement is to develop therapies for G protein-coupled receptor (GPCR) targets and further expanding the footprints in autoimmune diseases
  • Arena has a pipeline of three candidates APD418, Olorinab, and Etrasimod. Etrasimod is a qd, PO, selective sphingosine 1-phosphate (S1P) receptor modulator targeted for multiple immune-mediated inflammatory diseases including UC, Crohn’s disease, and atopic dermatitis

Click here to read full press release/ article | Ref: Arena | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post